Diabetes Drug News

Restricted access

New research shows that an existing type 2 diabetes drug also significantly decreases the risk of other serious conditions. A study published in the New England Journal of Medicine demonstrated that the drug canagliflozin, in addition to helping to treat 2 diabetes, also seems to significantly lower the risk of cardiovascular disease (CVD) and kidney disease in patients with diabetes, Reuters reported.

Renal-related events specifically were to be measured as part of a post-approval safety exploration of canagliflozin (brand name Invokana and Invokamet, Janssen Pharmaceuticals, a Johnson and Johnson company). The published research combined the new